Medical economics and the assessment of value in cardiovascular medicine: Part II.
Publication
, Journal Article
Mark, DB; Hlatky, MA
Published in: Circulation
July 30, 2002
Duke Scholars
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
July 30, 2002
Volume
106
Issue
5
Start / End Page
626 / 630
Location
United States
Related Subject Headings
- Stents
- Randomized Controlled Trials as Topic
- Quality-Adjusted Life Years
- Platelet Aggregation Inhibitors
- Myocardial Revascularization
- Humans
- Economics, Medical
- Cost-Benefit Analysis
- Coronary Artery Bypass
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., & Hlatky, M. A. (2002). Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation, 106(5), 626–630. https://doi.org/10.1161/01.cir.0000021408.40925.63
Mark, Daniel B., and Mark A. Hlatky. “Medical economics and the assessment of value in cardiovascular medicine: Part II.” Circulation 106, no. 5 (July 30, 2002): 626–30. https://doi.org/10.1161/01.cir.0000021408.40925.63.
Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation. 2002 Jul 30;106(5):626–30.
Mark, Daniel B., and Mark A. Hlatky. “Medical economics and the assessment of value in cardiovascular medicine: Part II.” Circulation, vol. 106, no. 5, July 2002, pp. 626–30. Pubmed, doi:10.1161/01.cir.0000021408.40925.63.
Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part II. Circulation. 2002 Jul 30;106(5):626–630.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
July 30, 2002
Volume
106
Issue
5
Start / End Page
626 / 630
Location
United States
Related Subject Headings
- Stents
- Randomized Controlled Trials as Topic
- Quality-Adjusted Life Years
- Platelet Aggregation Inhibitors
- Myocardial Revascularization
- Humans
- Economics, Medical
- Cost-Benefit Analysis
- Coronary Artery Bypass
- Cardiovascular System & Hematology